Ipamorelin vs CJC-1295: A Research Comparison

Ipamorelin and CJC-1295 are two of the most studied compounds in growth-hormone-axis research, and they are commonly investigated together because they act on different receptors. This article compares ipamorelin vs CJC-1295 for laboratory research only. Neither compound is for human or animal use, and nothing here is medical advice.

Two Different Receptor Classes

The central distinction is mechanism class:

• Ipamorelin is a selective growth-hormone-releasing peptide (GHRP), a pentapeptide that acts as a ghrelin/growth-hormone-secretagogue-receptor agonist. It is noted in the literature for selectivity, meaning it is studied for growth-hormone-axis signaling with comparatively limited effect on other hormones in models.
• CJC-1295 is a growth-hormone-releasing hormone (GHRH) analog based on the GHRH(1-29) sequence. It engages the GHRH receptor rather than the ghrelin receptor.

Why They Are Studied Together

Because a GHRP and a GHRH analog act through complementary pathways, research designs frequently pair them to study additive or synergistic effects on the growth-hormone axis in vitro and in animal models. Puritide Research offers a combined CJC No DAC / Ipamorelin preparation for teams studying the two together in a single reconstitution.

DAC and Duration

CJC-1295 exists in two research forms, with and without a Drug Affinity Complex (DAC), which changes its duration profile. For that comparison, see CJC-1295 DAC vs No DAC. Ipamorelin itself is short-acting in models, which is one reason it is often studied alongside a GHRH analog.

Handling and Quality

Both are supplied lyophilized and verified to at least 99% purity by third-party HPLC and mass spectrometry, each with a batch certificate of analysis. See the ipamorelin mechanism of action and CJC-1295 mechanism of action articles for compound-specific detail.

Common Research Questions

Why are ipamorelin and CJC-1295 studied together? They act on different receptors, a GHRP and a GHRH analog, so pairing them lets researchers study complementary or synergistic effects on the growth-hormone axis in models.

Is ipamorelin more selective than CJC-1295? Selectivity is defined against different receptor targets, so the two are not ranked on one scale. Ipamorelin is noted for selective ghrelin-receptor signaling; CJC-1295 selectively targets the GHRH receptor.

Summary

Ipamorelin is a selective GHRP; CJC-1295 is a GHRH analog. They are complementary research tools, not substitutes. Explore Ipamorelin, CJC-1295 No DAC, and the CJC No DAC / Ipamorelin preparation, all research use only.